Browse > Article
http://dx.doi.org/10.14776/piv.2020.27.e5

Outcome of High Dose AmpicillinSulbactam and Colistin Combination Therapy for Treating VentilatorAssociated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii: a Pilot Study  

Jeong, Seong Hee (Department of Pediatrics, Pusan National University Children's Hospital)
Kim, Young A (Department of Pediatrics, Pusan National University Children's Hospital)
Choi, Go-eun (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan)
Park, Su Eun (Department of Pediatrics, Pusan National University Children's Hospital)
Publication Information
Pediatric Infection and Vaccine / v.27, no.1, 2020 , pp. 45-52 More about this Journal
Abstract
Purpose: This pilot study aimed to evaluate the efficacy of high dose ampicillin-sulbactam and colistin combination therapy for ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) in the pediatric intensive care unit of Pusan National University Children's Hospital. Methods: We retrospectively reviewed 17 pediatric patients with VAP caused by CRAB from June 2017 to August 2018. Ten (58.8%) patients were treated with high dose ampicillin-sulbactam and colistin combination therapy (combination therapy group), whereas 7 were treated with colistin only or with various combinations with or without colistin (other antibiotics group). Clinical and bacteriological outcomes were compared between the groups. Results: The mean duration of fever after antibiotic use was 1.30±1.70 days in the combination therapy group and 1.71±1.49 days in the other antibiotics group. The mean duration of days for negative conversion of endotracheal aspirate bacterial culture after antibiotic therapy was 3.40±1.71 days in the combination therapy group and 11.80±8.86 days in the other antibiotics group. The mortality rate within 30 days of antibiotic therapy was 1/10 (10%) in the combination therapy group and 3/7 (42.9%) in the other antibiotics group. Conclusions: High dose ampicillin-sulbactam and colistin combination therapy as early antibiotic treatment in VAP caused by CRAB in children could improve clinical outcomes.
Keywords
Acinetobacter baumannii; Carbapenem-resistant; Colistin; Ampicillin-Sulbactam; Ventilator-associated pneumonia; Children;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Pogue JM, Neelakanta A, Mynatt RP, Sharma S, Lephart P, Kaye KS. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis 2014;59 Suppl 6:S388-93.   DOI
2 Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014;33:1311-22.   DOI
3 Kim YA, Park YS. Epidemiology and treatment of antimicrobial-resistant gram-negative bacteria in Korea. Korean J Intern Med 2018;33:247-55.   DOI
4 Bae IK, Jeong SH, Lee K. Carbapenem-resistant Acinetobacter baumannii. Korean J Clin Microbiol 2012;15:1-8.   DOI
5 Park SY, Lee EJ, Kim T, Yu SN, Park KH, Lee MS, et al. Early administration of appropriate antimicrobial agents to improve the outcome of carbapenem-resistant Acinetobacter baumannii complex bacteraemic pneumonia. Int J Antimicrob Agents 2018;51:407-12.   DOI
6 Lee HJ, Lee DG. Carbapenem-resistant Enterobacteriaceae: recent updates and treatment strategies. J Korean Med Assoc 2018;61:281-9.   DOI
7 Logan LK. Carbapenem-resistant enterobacteriaceae: an emerging problem in children. Clin Infect Dis 2012;55:852-9.   DOI
8 Makris D, Petinaki E, Tsolaki V, Manoulakas E, Mantzarlis K, Apostolopoulou O, et al. Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study. Indian J Crit Care Med 2018;22:67-77.   DOI
9 Hsu AJ, Tamma PD. Treatment of multidrug-resistant gram-negative infections in children. Clin Infect Dis 2014;58:1439-48.   DOI
10 Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI document M100-S25. Wayne: Clinical and Laboratory Standards Institute, 2015.
11 Skrupky LP, McConnell K, Dallas J, Kollef MH. A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria. Crit Care Med 2012;40:281-4.   DOI
12 Mularoni A, Bertani A, Vizzini G, Gona F, Campanella M, Spada M, et al. Outcome of transplantation using organs from donors infected or colonized with carbapenem-resistant gram-negative bacteria. Am J Transplant 2015;15:2674-82.   DOI
13 Choi SJ, Moon CJ, Chun YH, Yoon JS, Kim HH, Kim JT, et al. PRISM III in a pediatric intensive care unit with multiple disease entities. Korean J Crit Care Med 2011;26:123-7.   DOI
14 Ko KS, Choi Y, Lee JY. Old drug, new findings: colistin resistance and dependence of Acinetobacter baumannii. Precis Future Med 2017;1:159-67.   DOI
15 Lee K, Yong D, Jeong SH, Chong Y. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J 2011;52:879-91.   DOI
16 Kim MJ, Lee HJ, Son SH, Huh JW. Outbreak of Acinetobacter septicemia in a neonatal intensive care unit. Korean J Pediatr 2006;49:494-9.   DOI